Replies to post #210418 on Biotech Values

[seschm]

(TRIL)This is from Biomaven on the SI Biotech Valuation board

http://www.siliconinvestor.com/readmsg.aspx?msgid=31056707

There are some more encouraging details in a Ladenburg report.

>>1 MRD+ AML pts achieved complete molecular remission quickly after
4 weekly TTI-621 infusions and remain in ongoing remission for 15+ weeks. This
pts was refractory/relapse (r/r) from multiple prior therapies including allogeneic HSCT,
which usually suggests poor prognosis. This pts is the only MRD+ AML pts treated, thus
1/1 r/r MRD+ AML pts achieved CMR so far after TTI-621 treatment.

Also, 3/6 lymphoma pts achieved and remain in ongoing PMR with tumor shrinkage
for 19+ (DLBCL), 18+ (transformed lymphoma), and 8+ weeks (follicular lymphoma)
with weekly infusion of TTI-621 and Rituxan. The PMR are determined by Lugano
2014 criteria (Exhibit 1), which recommends using PET-CT metabolic uptake and the
5-point scale as the standard response criteria for FDG-avid lymphoma (e.g. DLBCL,
HL, FL) rather than CT scan-based tumor size change, as PET-CT is shown to be more
accurate and prognostic for outcome than CT for FDG-avid lymphoma (Cheson BD et al.
J Clin Oncol. 2014). A PMR at interim analysis using the Lugano 2014 criteria indicates
responding pts (Exhibit 1). Thus, 3/6 lymphoma pts responded to TTI-621 + Rituxan. Note
that these pts have been r/r from multiple prior therapies and all pts were r/r from prior
Rituxan treatments.<<

I added here.

Peter